Authors
Latest:
Drugs in Perspective: Liraglutide for the treatment of obesityLiraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that received FDA approval for the treatment of diabetes mellitus in 2010. The mechanism of action includes slowing gastric emptying, increasing glucose-dependent insulin secretion, decreasing inappropriate glucagon release, and instilling a feeling of satiety. Liraglutide is administered once daily by subcutaneous injection. Common adverse effects of liraglutide include nausea (28%), diarrhea (17%), vomiting (11%), and constipation (10%).
Latest:
New study shows warfarin weekly self-testers achieve better control with management by exception protocolIn a study recently published in Nursing 2014, atrial fibrillation patients on warfarin therapy who self-tested their coagulation (via international normalized ratio [INR]) and were remanaged by their clinicians using a “Management by Exception” protocol had better warfarin control than traditional self-testers.1 The protocol, in which patients followed specific clinic-issued, written instructions for managing out-of-range INR self-test results within a predetermined safety range, also benefited clinics by reducing the need for telephone follow-up and related costs.
Latest:
The role of pharmacists evolving in the team-based approach to medical carePharmacists can play an influential role in ensuring patient access to quality health care by both encouraging and enhancing patient medication adherence and increasing patient knowledge of their disease states and medication therapies.
Latest:
Examining correlations between pharmaceutical nonadherence and 30-day hospital readmissionsRightCare’s software, based on 10 years of academic and clinical research, has been proven to reduce readmission rates by as much as 35%.
Latest:
Drugs in Perspective: Zykadia (ceritinib)Zykadia (ceritinib) is a tyrosine kinase inhibitor that was approved by FDA on April 29, 2014, as a medication for the treatment of patients with ALK-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib.
Latest:
Sun Pharma Recalls 1 Lot of Metformin Due to NDMA LevelsSun Pharmaceuticals issued a voluntary recall of 1 lot of its metformin hydrochloride for extended-release (ER) oral suspension (Riomet ER), 500 mg per 5 mL.
